MarketCap
Facebook
X
TelegramGeschäftsbericht 2022
hinzugefügt 31.03.2023
Ayala Pharmaceuticals Gesamtverbindlichkeiten 2011-2026 | AYLA
Gesamtverbindlichkeiten Jährlich Ayala Pharmaceuticals
| 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| - | - | 7.43 M | 5.6 M | 49 M | - | - | - | - | - | - | - |
Alle Zahlen in USD-Währung
Indikatorenreichweite aus Jahresberichten
| Höchstwert | Mindestwert | Durchschnitt |
|---|---|---|
| 49 M | 5.6 M | 20.7 M |
Gesamtverbindlichkeiten anderer Aktien in der Pharmaeinzelhändler
| Name | Gesamtverbindlichkeiten | Preis | % 24h | Marktkapitalisierung | Land | |
|---|---|---|---|---|---|---|
 |
MorphoSys AG
MOR
|
1.98 B | - | 2.43 % | $ 254 M |  Germany |
 |
BioNTech SE
BNTX
|
2.76 B | $ 97.54 | 2.14 % | $ 27.2 B | Germany |
 |
Aligos Therapeutics
ALGS
|
35 M | $ 8.65 | 8.19 % | $ 85.5 M |  USA |
 |
Alterity Therapeutics Limited
ATHE
|
5.89 M | $ 3.63 | -2.42 % | $ 8.73 B |  Australia |
 |
I-Mab
IMAB
|
707 M | - | - | $ 866 M |  China |
 |
AlloVir
ALVR
|
42.9 M | - | 4.14 % | $ 49.1 M | USA |
 |
Applied Molecular Transport
AMTI
|
46.6 M | - | - | $ 10.1 M | USA |
 |
Alexion Pharmaceuticals, Inc.
ALXN
|
6.45 B | - | - | $ 40.3 B | USA |
 |
Genfit SA
GNFT
|
215 M | - | 2.54 % | $ 160 B |  France |
 |
Biophytis SA
BPTS
|
20.4 M | - | -13.47 % | $ 169 M | France |
 |
Applied Therapeutics
APLT
|
72 M | - | - | $ 8.42 M | USA |
 |
EyeGate Pharmaceuticals, Inc.
EYEG
|
8.16 M | - | -1.52 % | $ 24.7 M | USA |
 |
Midatech Pharma plc
MTP
|
6.77 M | - | -18.52 % | $ 27.3 M |  Britain |
 |
Esperion Therapeutics
ESPR
|
768 M | $ 2.14 | -1.38 % | $ 445 M | USA |
 |
Evogene Ltd.
EVGN
|
8.07 M | $ 0.81 | -0.07 % | $ 27.9 M |  Israel |
 |
Amphastar Pharmaceuticals
AMPH
|
840 M | $ 20.47 | 0.49 % | $ 957 M | USA |
 |
Genmab A/S
GMAB
|
2.02 B | $ 28.2 | -0.18 % | $ 18 B |  Danmark |
 |
Grifols, S.A.
GRFS
|
12.8 B | $ 8.19 | -0.24 % | $ 6.83 B |  Spain |
 |
GT Biopharma
GTBP
|
1.32 M | $ 0.36 | -2.82 % | $ 1.98 M | USA |
 |
Acorda Therapeutics
ACOR
|
395 M | - | -24.86 % | $ 820 K | USA |
 |
Институт стволовых клеток человека
ISKJ
|
1.1 B | - | - | - |  Russia |
 |
Halozyme Therapeutics
HALO
|
2.48 B | $ 67.06 | -1.12 % | $ 8.04 B | USA |
 |
Adverum Biotechnologies
ADVM
|
109 M | - | - | $ 86.2 M | USA |
 |
Advaxis
ADXS
|
7.89 M | - | -9.65 % | $ 45.9 M | USA |
 |
Aeterna Zentaris
AEZS
|
17.6 M | - | 5.93 % | $ 314 M |  Canada |
 |
AgeX Therapeutics
AGE
|
6.99 M | - | -10.17 % | $ 12.2 K | USA |
 |
Harmony Biosciences Holdings
HRMY
|
401 M | $ 28.69 | -0.69 % | $ 1.65 B | USA |
 |
Aeglea BioTherapeutics
AGLE
|
62.5 M | - | - | $ 1.01 B | USA |
 |
Akebia Therapeutics
AKBA
|
344 M | $ 1.41 | 0.71 % | $ 363 M | USA |
 |
Applied Genetic Technologies Corporation
AGTC
|
37.2 M | - | - | $ 26.5 M | USA |
 |
Allakos
ALLK
|
74.8 M | - | - | $ 28.6 M | USA |
 |
Can-Fite BioPharma Ltd.
CANF
|
3.45 M | $ 2.96 | 1.37 % | $ 4.87 M | Israel |
 |
Aptinyx
APTX
|
28.4 M | - | -39.0 % | $ 4.57 M | USA |
 |
Aquestive Therapeutics
AQST
|
194 M | $ 4.16 | 1.84 % | $ 445 M | USA |
 |
Aravive
ARAV
|
51.5 M | - | -13.39 % | $ 1.45 M | USA |
 |
Arcutis Biotherapeutics
ARQT
|
243 M | $ 24.01 | -0.85 % | $ 3.05 B | USA |
 |
ImmuCell Corporation
ICCC
|
15.5 M | $ 7.12 | 1.14 % | $ 64.3 M | USA |
 |
AIkido Pharma
AIKI
|
43.5 M | - | 1.93 % | $ 17.4 M | USA |
 |
Celldex Therapeutics
CLDX
|
55.8 M | $ 32.24 | - | $ 2.14 B | USA |
 |
Autolus Therapeutics plc
AUTL
|
411 M | $ 1.48 | -0.67 % | $ 394 M | Britain |
 |
Aptose Biosciences
APTO
|
37.2 M | - | -45.71 % | $ 1.2 M | Canada |
 |
Cidara Therapeutics
CDTX
|
51.5 M | - | - | $ 1.41 B | USA |
 |
Incyte Corporation
INCY
|
1.79 B | $ 94.86 | -1.26 % | $ 18.5 B | USA |
 |
AVROBIO
AVRO
|
6.35 M | - | 1083.1 % | $ 745 M | USA |
 |
Aytu BioScience
AYTU
|
93.3 M | $ 2.61 | 2.35 % | $ 16.4 M | USA |
 |
InflaRx N.V.
IFRX
|
13.7 M | $ 1.05 | 4.5 % | $ 152 M | Germany |
 |
AstraZeneca PLC
AZN
|
65.4 B | - | - | $ 96.9 B | Britain |
 |
Inventiva S.A.
IVA
|
226 M | $ 5.18 | -1.52 % | $ 138 M | France |